Related Experiment Videos
Clinically important drug interactions with disease-modifying antirheumatic drugs
1Department of Rheumatology, Medisch Spectrum Twente, Enschede and Twenteborg Ziekenhuis, Almelo, The Netherlands. chaagsma@worldonline.nl
Drugs & Aging
|November 7, 1998
Summary
Managing drug interactions is crucial for patients with rheumatic diseases on long-term treatments like disease-modifying antirheumatic drugs (DMARDs). Careful consideration of drug combinations, especially in elderly patients with comorbidities, helps prevent adverse effects and ensures treatment efficacy.
Area of Science:
- Rheumatology
- Clinical Pharmacology
Background:
- Rheumatic diseases often require chronic treatment with disease-modifying antirheumatic drugs (DMARDs).
- Polypharmacy and comorbidities, particularly in the elderly, increase the risk of drug interactions.
- Understanding drug interactions is vital for safe and effective management of rheumatic conditions.
Purpose of the Study:
- To review clinically significant drug interactions associated with commonly used disease-modifying antirheumatic drugs (DMARDs).
- To highlight potential interactions involving methotrexate and cyclosporine in rheumatological practice.
Main Methods:
- Literature review of drug interactions concerning disease-modifying antirheumatic drugs (DMARDs).
- Focus on interactions affecting renal excretion (methotrexate) and metabolic degradation (cyclosporine).
Main Results:
- Antimalarials, gold, penicillamine, sulfasalazine, and azathioprine have limited clinically significant drug interactions.
- Methotrexate's renal excretion is influenced by drugs affecting kidney function and folate metabolism (e.g., trimethoprim).
- Cyclosporine exhibits numerous significant drug interactions due to cytochrome P450 3A metabolism interference, impacting drug concentrations and clinical outcomes.
Conclusions:
- Awareness and management of drug interactions are essential for optimizing therapy in rheumatic diseases.
- Particular attention is needed for methotrexate and cyclosporine due to their interaction profiles.
- Proactive management of drug interactions can prevent toxicity and improve therapeutic efficacy in rheumatology patients.